Background: Patients with ulcerative colitis (UC) are at risk of developing colorectal cancer. We have previously reported that cancer progression is
U lcerative colitis (UC) is a chronic inflammatory disease that affects approximately 593,000 individuals in the United States, and its prevalence is steadily increasing.
1,2 It has 2 peaks of incidence: one between 25 and 35 years of age (early onset) and another one between 55 and 65 years of age (late onset). 2 It is widely accepted that patients with UC have an increased risk of colorectal cancer, although recent epidemiological studies suggest that the increased risk is limited to patients with early age of onset, extensive disease, and long disease duration. 3, 4 A variety of other important clinical differences between patients with UC with early-onset and late-onset of disease have been reported. Late-onset patients seem to have a less aggressive clinical course 5 and better response to therapy. 6 However, if neoplasia develops, it tends to arise in fewer years than in early-onset patients 7 and it tends to be localized instead of widespread. 8 Given the aging of the population and the increasing prevalence of UC, it is crucial to determine the molecular pathways that underlie these differences to develop cancer biomarkers that can inform the clinical management of these patients.
Tumorigenesis in UC is a multistep process that involves progression through low-grade dysplasia, high-grade dysplasia (HGD), and cancer. 9 Current guidelines recommend that patients with UC with more than 8 years of disease duration undergo colonoscopy every 1 to 2 years for early detection of dysplasia. 10 Because UC-associated dysplasia is often flat and difficult to visually identify, 4-quadrant biopsies from every 10 cm of the colon are typically collected at colonoscopy for histological examination.
This intensive surveillance protocol is time-consuming, expensive, and uncomfortable for the patient. Moreover, it is biased toward identifying larger more advanced neoplasia, given the probabilistic nature of arbitrary sampling. Patients with UC would greatly benefit from more sensitive biomarkers of cancer risk that could detect preneoplastic alterations that precede the appearance of histological changes.
We recently developed a technique that enables the detection of preneoplastic clonal expansions in histologically normal colon biopsies from patients with UC with cancer elsewhere in the colon. 11 The technique is based on the identification of clonal mutations in polyguanine tracts, which are short series of guanine repeats found mostly in intergenic and intronic areas of the genome. These repetitive tracts are highly prone to insertions and deletions, with a mutation rate on the order of ;10 24 per cell generation. 12 Because they are mutated so readily, individual patterns of mutation can serve as a convenient marker of cell lineage. When a polyguanine mutation is detected in a colon biopsy, it indicates the presence of a clonal expansion, that is, an abnormal proliferation of cells. Most of these mutations do not confer any specific proliferative advantage, but rather, are simply inherited by daughter cells as "passengers" on sweeps of clonal evolution driven by mutations and epimutations elsewhere in the genome. In our initial study, we found genetically related clonal expansions in nondysplastic biopsies both immediately surrounding and distant from cancer, suggesting that such clonal fields precede dysplasia in UC. 11 Moreover, these preneoplastic clones were rarely found in patients without cancer, making them an attractive biomarker of concurrent, and potentially future, cancer in UC.
The presence of molecular alterations in histologically normal epithelium that surrounds cancer is known as "field cancerization" or "field effect." 13 We previously demonstrated that in UC, such fields comprise cells harboring aneuploidy, p53 mutations, and chromosomal instability, [14] [15] [16] and can extend many centimeters along the colon. 16 These fields are also characterized by shorter telomeres, increased DNA damage, and increased senescence, which occurs in association with chronic inflammation. 17 Our working hypothesis is that inflammation leads to telomere shortening through reactive oxygen species, which damage and shorten telomeres. 18 Shorter telomeres lead to senescence in the presence of proficient checkpoints (p53, p16) 19 but, in the absence of checkpoints, lead to fusion-bridge-breakage cycles and self-perpetuating chromosomal instability. 20 In this model, telomere shortening is an early event that might precede clonal outgrowth, but it is also likely that clonal expansion accelerates telomere shortening due to the end-replication problem. Regardless of the order of events, clonal expansions 11 and shorter telomeres 17, 20 are more frequent in nondysplastic biopsies of patients with UC with HGD or cancer (UC progressors) than patients with UC without (UC nonprogressors). The aim of this study was to validate those results in an independent case-control study and to explore the associations between clonal expansion, telomere shortening, and the clinicopathological characteristics of patients with UC to further characterize their potential as clinical biomarkers.
MATERIALS AND METHODS

Patients and Biopsies
Thirty-three patients with UC who underwent colectomy at the Cleveland Clinic between 2005 and 2009 were included in this study. The clinicopathological characteristics of the patients are presented in Table 1 . Nineteen patients without HGD or cancer were classified as "nonprogressors." Fourteen patients with at least 1 biopsy with HGD or cancer were classified as "progressors." The indication for colectomy in UC progressors was a diagnosis of HGD or cancer at colonoscopy, whereas for UC nonprogressors was intractability of symptoms. All patients had documented pancolitis except for 7, in whom information on extent of disease was unavailable. Only 1 patient presented with primary sclerosing cholangitis. Biopsies obtained at colectomy were divided, with one half frozen at 2708C in minimal essential medium with 10% dimethyl sulfoxide and the other fixed and sectioned for histology. Diagnosis of dysplasia was performed by an expert gastrointestinal pathologist (M.P.B.). For each patient, 3 to 8 nondysplastic biopsies (mean, 5) obtained from distal, mid, and proximal colon were analyzed, totaling 188 biopsies. For all biopsies, the distance to rectum and the site of nearest HGD or cancer was recorded. For progressors, an additional 9 dysplastic biopsies were collected for separate analysis. For all colons in the study, a muscularis sample was collected for defining normal germline genotype. All protocols were approved by Human Subjects Review Boards at the Cleveland Clinic and University of Washington.
Epithelial Cell Isolation and DNA Extraction
Epithelial cells from frozen biopsies were isolated by EDTA shake off as previously described. 16 This method yields 90% enrichment for epithelial cells. DNA was extracted by silica filtration columns (Qiagen, Hilden, Germany) and quantified by Nanodrop UV spectroscopy (Thermo Scientific, Waltham, MA).
Polyguanine Tract-length Genotyping
Genotyping of the 17 polyguanine loci listed in Figure, Supplemental Digital Content 1, http://links.lww.com/IBD/A290, was carried out for each sample in a blinded fashion using the primers and protocol previously described. 11 Briefly, 2 ng of DNA was used to seed PCR reactions with each fluorescently labeled primer set on robotically loaded 384-well plates. PCR products of compatible amplicon lengths and labels were appropriately diluted and combined for multiplex capillary fragment length analysis on an ABI 3730xl instrument. Resulting electropherograms were analyzed through a combination of automated software and caller-blinded visual assessment. Mutations were defined as genotypes differing from a patient's corresponding germline genotype obtained from a muscularis biopsy. Each genotyping reaction was carried out in triplicate, and the small number of ungenotypable amplification or sequencing failures (1.7%) were marked as such and not included in subsequent mutation frequency calculations.
Telomere Length Quantification
Telomere length was measured by quantitative PCR as previously described, 21 with minor modifications. The analysis was performed on the same DNA previously used for polyguanine genotyping. For each sample, 2 PCRs were performed: the first to amplify the telomeric DNA and the second to amplify a single-copy control gene (36B4, acidic ribosomal phosphoprotein PO). A 4-point standard curve (2-fold serial dilutions from 5 to 0.625 ng of DNA) was included in all PCRs to allow the transformation of cycle threshold into nanograms of DNA. All PCR reactions were performed in a Rotor-Gene Q (Qiagen) using 100-well discs and a reaction volume of 10 mL. Each reaction included 1· Rotor Gene Sybr green PCR master mix (Qiagen), 2.5 ng of DNA, and either 500 nM of each telomere primer or 1 mM of each control gene primer. All samples were run in triplicate, and the median was used for subsequent calculations. The amount of telomeric DNA was divided by the amount of control gene DNA, producing a relative measurement of the telomere length of the sample. Two control samples were run in each experiment to allow for normalization between P  CA  F  55  35  20  8  4  2  2  25  PG8  P  HGD  F  57  12  45  5  3  1  1  26  PG5  P  HGD  F  63  40  23  3  2  1  NA  27  PG15  P  CA  M  66  19  47  5  3  1  1  28  PG31  P  CA  M  67  37  30  8  4  2  2  29  PG20  P  CA  M  66  53  13  5  2  1  2  30  PG3  P  HGD  M  69  58  11  4  2  1  1  31  PG17  P  CA  F  71  64  7.5  5  2  2  1  32  PG6  P  CA  F  78  73  5  5  2  2  1  33  PG11  P  CA  M  86  81  5  5  2  2  1 experiments, and periodic reproducibility experiments were performed to guarantee correct measurements. The interassay variability (coefficient of variation) for this assay was 7%.
Statistical Analysis
Because multiple biopsies were analyzed for each patient, patients were first compared based on their mean values of percentage polyguanine mutations and telomere length. These associations were assessed using the t test and linear regression. Second, patients were compared based on the individual values of all the biopsies analyzed. For this analysis, the generalized estimating equations (GEE) method was used for regression as it accounts for correlation among multiple biopsies from a given patient. The discriminatory ability of the percentage of mutations and telomere length to classify patients as progressors or nonprogressors was evaluated using receiver operating characteristic (ROC) curves. Classification accuracy was quantified using the area under the ROC curve (AUC) and percentile-based 95% confidence intervals (CIs) were constructed by bootstrapping the data 1000 times. Age was controlled as a confounder by estimating covariate-adjusted ROC curves. 22 Optimal thresholds were obtained as the values that maximized sensitivity for a specificity of 80% or greater. Statistical analyses were performed using Stata (version 10) and R statistical software (version 2.14.1). All reported P values were 2-sided at an alpha level of 0.05.
RESULTS
Clonal Expansions and Telomere Length Characterize Different Subgroups of UC Progressors and Nonprogressors
We previously observed many polyguanine mutationdefined clones in the nondysplastic mucosa of UC progressors, but not in UC nonprogressors, 11 and here sought to validate these results in an independent cohort. A complete listing of clonal mutations found at each of the 17 polyguanine loci analyzed in DNA from nondysplastic colonic epithelium of 33 independent patients with UC is tabulated in Figure, Supplemental Digital Content 1, http://links.lww.com/IBD/A290. The percentage of mutant genotypes for each biopsy was calculated as the number of loci mutated divided by the number of loci genotyped. Figure 1 summarizes the mean percentage of mutations (Fig. 1A) and mean telomere length (Fig. 1B) , both calculated as the average of all nondysplastic biopsies analyzed for from each patient. UC progressors and nonprogressors are shading-coded according to their age of onset of disease and years of disease duration. As is readily observed, mutations were most frequent in UC progressor colons, but only in those with early onset of disease and long disease duration. The cut-off point of late onset of disease at 50 years of age is based on recent data regarding UC incidence in a U.S. cohort, 2 and the study of Ha et al, 6 which reported important clinical differences between patients with late-onset (older than 50 years at diagnosis) and early-onset UC. The cut-off point for long disease duration is 8 years, which is the clinically established starting time for colonoscopic surveillance based on previous epidemiological studies. 23 On average, early-onset UC progressors with long disease duration displayed 4 times more mutations than earlyonset UC non-progressors with long disease duration (17% versus 3.9%, t test P , 0.001, Fig. 1A) . Moreover, UC progressors with late-onset disease displayed an average of only 0.71% mutations per biopsy, 24 times less than the progressors with early-onset disease (t test P , 0.001, Fig. 1A ). These groups also differed in terms of their telomere length. Telomeres tended to be shorter in early-onset, long disease duration UC progressors than in both early-onset, long disease duration nonprogressors (0.476 versus 0.656, t test P ¼ 0.036), and late-onset UC Progressors (0.476 versus 0.702, t test P ¼ 0.057).
The presence of mutations in early-onset UC nonprogressors was associated with older age (Fig. 2A, Pearson' s r ¼ 0.520, P ¼ 0.039). This is in agreement with a variety of evidence indicating that, with age, mutations accumulate in various human organs and tissues, including colon. 24 While aging is also expected to shorten telomeres, the observed trend was not statistically significant for either earlyonset nonprogressors or progressors (Fig. 2B) . Interestingly, lateonset UC progressors showed remarkably low levels of mutations and long telomeres, despite being the eldest patients in the study.
To eliminate any potential confounding by age, we used ageadjusted ROC curves to analyze the ability of the percentage of mutations and telomere length to distinguish UC progressors and nonprogressors (Table 2) . Late-onset patients were excluded from this analysis because progression in these patients is not associated with clonal expansions or shorter telomeres, as noted above. We also excluded patients with less than 8 years disease duration because these patients have no epidemiologically increased risk of colorectal cancer 23 (accordingly, they showed very few clonal expansions) and were unfairly overrepresented in the nonprogressor group. Thus, the biomarker analysis was restricted to patients with early-onset UC with more than 8 years of disease duration (10 nonprogressors and 8 progressors). These 2 groups of patients could be distinguished with 100% sensitivity (8/8) and 80% specificity (8/10) using a threshold of 10% average frequency of mutations. Telomere length was a weaker classifier because there was no optimal threshold to maximize sensitivity without compromising specificity.
Clonal Expansions and Short Telomeres Are Present in Most Nondysplastic Biopsies from Early-onset UC Progressors, but in Few Biopsies of Nonprogressors
Within a given biopsy, the presence of a single mutant locus is sufficient to define a clone and indicate abnormal proliferation of the cell population. The co-occurrence of multiple mutations, however, suggests that the clone has either accumulated more passengers through sequential rounds of clonal outgrowth, has been exposed to more mutagenic damage before expansion, or, perhaps, is derived from a genetically unstable population. 25 To explore the clinical relevance of different degrees of mutation, we analyzed the percentage of mutant polyguanine genotypes for each biopsy of UC nonprogressors and UC progressors (only early-onset and .8 years disease duration, as discussed above, Fig. 3A) . Seven additional dysplastic biopsies from UC progressors were also assessed.
As expected, dysplastic biopsies yielded the highest percentage of mutations (mean, 40.4%; minimum, 23.5%; maximum, 58.8%). The average percentage of mutations in nondysplastic biopsies was statistically significantly higher by 14.1% among progressors compared with nonprogressors (95% CI, 6.5%-22.1%, P , 0.001). The estimated odds of having at least 1 mutation was 14.7 times higher in progressors compared with nonprogressors (95% CI, 3.8-56.4, P , 0.001). Despite the heterogeneity in the frequency of mutations, all but 1 progressor had at least 1 nondysplastic biopsy with more than 27.5% mutant genotypes, whereas all nonprogressors had all biopsies below that level (Fig. 3A) . This represents 100% specificity and 87.5% sensitivity ( Table 2 ). The single progressor without nondysplastic biopsies above the 27.5% threshold was the only case in the study that lacked complete colon coverage (case PG5, Table 1 ). This patient had a proximal cancer, and, unfortunately, no proximal nondysplastic biopsies were available for analysis.
Telomere length could not distinguish UC progressors from nonprogressors and the percentage of polyguanine mutations (Fig. 3B) . Using the GEE model that adjusted for age, the mean telomere length was significantly shorter among progressors compared with nonprogressors (0.13 units, 95% CI, 20.25 to 20.01, P ¼ 0.036). However, some nonprogressor biopsies showed relatively short telomeres, which compromised the discriminatory value of telomere length (Table 2) . Interestingly, a subset of these biopsies were the ones harboring polyguanine mutations, as shown by the significant negative association between telomere length and percentage of mutations (Fig. 3C , slope ¼ 20.010, 95% CI, 20.016 to 20.003, P ¼ 0.003 from GEE model). This indicates that clonal expansions are often accompanied by shorter telomeres, which might reflect telomere attrition due to multiple rounds of cell proliferation. A subset of biopsies, however, showed short telomeres without clonal expansions, which might be the consequence of telomere attrition secondary to oxidative damage. 18 In contrast to UC nonprogressors, among UC progressors, practically all biopsies had FIGURE 1. Clonal expansions and telomere length in patients with UC. For each patient, mean clonal mutations (A) and mean telomere length (B) were calculated as the mean of all nondysplastic biopsies analyzed per patient (mean, 5; range, [3] [4] [5] [6] [7] [8] . The same biopsies were analyzed in both assays. Age, disease duration (years), and age of onset are indicated for each patient on the x axes. Patients are grouped by nonprogressor and progressor status and shading-coded to facilitate group comparisons. White: patients with age of onset ,50 years and disease duration ,8 years; light gray: patients with age of onset ,50 years and disease duration .8 years; dark gray: patients with age of onset .50 years. Patients without bars on (A) do not have any mutant genotypes. P values correspond to t tests.
relatively short telomeres and frequent clonal expansions, hence the lack of association between the two (Fig. 3D , slope ¼20.002, 95% CI, 20.006 to 0.002, P ¼ 0.361). Dysplastic biopsies showed very short telomeres and, as noted previously, the highest degree of mutations.
Biopsies Closer to Dysplasia Show Higher Percentage of Mutations
We next investigated if the variation in the percentage of mutant polyguanine genotypes of different biopsies was associated with position in the colon. Among nondysplastic biopsies, a very strong association was found between the percentage of mutations in nondysplastic biopsies and the proximity to dysplasia (Fig. 4A) , but not between the percentage of mutations and the distance to rectum (Fig. 4B) . The average percentage of mutations was estimated to decrease by 2.7% for a 10-cm increase in distance from dysplasia (95% CI, 24.4 to 21.0, P ¼ 0.002 from GEE model). Dysplastic biopsies (located at distance ¼ 0 in Fig. 4A) showed the highest percentage of mutations. We additionally plotted the association between percentage of mutations and distance to dysplasia for each patient (Fig., Supplemental Digital Content 2, http://links.lww.com/IBD/A291) and found that although the percentage of mutations varied between patients, all but 2 patients showed a greater mutation frequency closer to dysplasia. Telomere length was not significantly associated with distance to dysplasia (Fig. 4C ) or distance to rectum (Fig. 4D) .
Classification of UC Progressors and Nonprogressors Based on the Analysis of Clonal Expansions and Telomere Length Using Only 3 Biopsies
With the goal of translating our clonal analysis into a clinically practical test to identify patients with UC at risk of cancer, assay simplification and standardization are required. Thus, we compared the ability of clonal mutations to distinguish UC progressors from nonprogressors using all the biopsies in the study (Table 2) versus only 3 randomly selected biopsies collected from distal, mid, and proximal colon (Table 3) . We reasoned that 3 biopsies along the colon might suffice because despite higher level of mutations closer to dysplasia, most biopsies from UC progressors had at least 1 mutation, which was not the case for †Progressor undetected was only patient in the study with incomplete colon coverage. ‡Sensitivity is estimated as the proportion of progressors with telomere length below optimal threshold and specificity as the proportion of nonprogressors with telomere length above optimal threshold.
UC nonprogressors (Fig. 3A) . The discriminatory performance of percentage of mutations and telomere length was found to be only slightly decreased when using 3 biopsies compared with all biopsies. The mean percentage of mutations showed the best discriminatory value with 87.5% sensitivity (as above, the patient missed was the one with incomplete colon coverage) and 90% specificity.
Clonal Expansion Analysis Could Be Simplified with a Reduced Number of Polyguanine Markers
From the summary of mutations by marker (Fig. A , Supplemental Digital Content 3, http://links.lww.com/IBD/A292), it is readily apparent that certain polyguanine loci are more frequently informative than others. This suggests the possibility of simplifying the analysis by using only the most informative markers. To investigate the discriminatory power of each marker, we calculated the AUC for all possible combinations of all 17 markers. For combinations that fell into varying levels of performance based on the AUC intervals, we calculated the proportion of combinations that contained each marker. Markers that were often present in combinations that had high AUC values and rarely present in combinations that had low AUC values would be potential candidates for simpler marker combinations (Fig. B , Supplemental Digital Content 3, http://links.lww.com/IBD/A292). We identified 24,419 different combinations of markers that produced an AUC higher than 0.95 (the best discriminatory value between progressors and nonprogressors). The marker with the best discriminatory power appeared in 90% of these combinations, with the next most frequent markers present in 70% and 64% of the combinations, followed by several markers present in about half of the combinations. When calculating the percentage of mutations using only the 3 best discriminatory markers, we could, as expected, maximize discrimination between progressors and nonprogressors (100% sensitivity and 90% specificity; Fig. C , Supplemental Digital Content 3, http://links.lww.com/IBD/A292). Although this limited marker panel remains to be validated in a larger study, it offers the possibility of a simpler assay by using only the most informative polyguanine loci.
DISCUSSION
The goal of this study was to validate clonal expansions and telomere shortening as cancer biomarkers in UC. We previously reported that clonal expansions-defined by length altering mutations in polyguanine tracts-occur at much higher frequency in nondysplastic biopsies of UC progressors than nonprogressors. 11 We also demonstrated that nondysplastic biopsies from UC progressors show shorter telomeres than those from UC nonprogressors. 17, 20 In this report, we independently confirmed these original findings but, intriguingly, discovered that they apply only to (disease arising before 50 years of age) patients with early-onset UC. Late-onset UC progressors lacked clonal expansions and displayed longer telomeres, suggesting that they might follow a different mechanism of tumor progression. For early-onset progressors, clonal expansions were significantly better markers of progression than short telomeres. Mean frequency of clonal expansions could discriminate early-onset progressors from nonprogressors with 100% sensitivity and 80% specificity, which is in close agreement with our original study. 11 This confirms its value as a biomarker for the detection, and potentially prediction, of cancer risk in UC.
The age-of-onset-dependent effect on clonal expansions could not have been observed in our first study because all progressors in the initial cohort had early-onset of disease. Its discovery in this validation set was unanticipated but lends biological substantiation to recent studies that have reported important clinical and epidemiological differences between early-onset and 7 This is reflected in the late-onset progressors in our study, 2 of which had UC for less than 8 years. Although the number of patients is small, our results provide the first molecular evidence that the mechanism of tumorigenesis in late-onset progressors might be different from early-onset progressors. Additional investigations are needed to confirm these results because they have significant clinical implications. If late-onset progressors develop cancer in less than 8 years, then these patients should be enrolled earlier for colonoscopic surveillance. Moreover, if colorectal cancer does not arise as a consequence of underlying colitis and widespread preneoplastic clones, these patients might safely benefit from partial colon resection, such as is done with sporadic colorectal cancer patients, to spare them the morbidity of full colectomy.
A simple mechanistic explanation of why tumors in lateonset disease uniquely arise in the absence of preneoplastic fields and shortened telomeres is not obvious. It is possible that some of these cancers might simply be sporadic colorectal carcinomas (inherently more prevalent in the elderly 26 ) that coincidentally arose in the background of UC. Sporadic colorectal cancers in patients without UC do not show a field effect of telomere shortening 27 like the colorectal cancers observed in the patients with late-onset UC. Alternatively, UC might accelerate transformation of preexisting age-associated adenomas into colorectal cancers, which could explain the clinical observation that progression to cancer seems to be more rapid in late-onset than in early-onset UC. 7 Of greatest interest is the possibility that the nature of colitis and its progression to cancer is fundamentally different in late-onset patients compared with early-onset patients. In agreement with this notion, 2 different types of UC-associated colorectal cancer have been described: (1) widespread neoplasia, which exhibits coexisting diffusely scattered dysplasia and is associated with early-onset of disease, and (2) localized neoplasia, in which cancers tend to be unifocal and without accompanying dysplastic changes and is associated with lateonset of disease. 8 Our results suggest that widespread neoplasia is likely to be the consequence of diffuse telomere shortening and clonal expansions, as observed in the colon of early-onset UC progressors. In these patients, critically short telomeres may lead to chromosomal instability and tumor progression through cycles of chromosome bridge-breakage-fusion. 20 In contrast, late-onset progressors develop localized neoplasia in the absence of widespread genetic alterations, consistent with alternative mechanisms driving tumor development in this elderly population.
Consistent with our previous data, nondysplastic clones remained a strong biomarker of concurrent cancer or HGD elsewhere in the colon. In this validation study, we observed a higher percentage of clone-defining mutations than seen previously in both progressors and nonprogressors, which likely reflects the use of a smaller number of more informative markers and more uniform biopsy coverage of colons. Nevertheless, at an optimal ROC-defined mutation threshold, the sensitivity and specificity for distinguishing the 2 groups were almost identical to that previously reported (100% sensitivity and 80% versus 88% specificity). That some nonprogressors exhibit clones is to be expected when considered in the context that malignant transformation is a temporally graded process and carcinoma seems to arise from within preexisting clones. 11 A subset of nonprogressors are destined to become future progressors, and while the ability to predict concurrent malignancy will be clinically useful, a more significant possibility is that the abundance of mutant clones will predict the risk of future progression. The ability to more precisely risk stratify patients with UC would allow redistribution of surveillance efforts to focus on the small subset at greatest risk while potentially scaling back expensive and uncomfortable monitoring in the majority of patients who will never develop cancer. The expansion of preneoplastic clones has been documented by other techniques in different premalignant conditions of the gut. 28 The analysis of polyguanine mutations provides a highly sensitive method to detect these clones, and, as such, it has the potential for early cancer detection, not only in UC but also in other gastrointestinal neoplastic process. Future longitudinal studies will be necessary to address these questions.
With the goal of clinical translation, we explored several assay refinements to minimize laboratory processing time and sampling requirements. In this study, we halved the number of polyguanine loci interrogated in the last study to eliminate those that performed poorly. We also computationally simulated the most efficient subpanels of markers that could be used to further reduce the number of PCR reactions needed without compromising sensitivity or specificity. In addition, we examined the number of biopsies tested per person and found that 3 widely spaced samples performed nearly and a larger set for distinguishing UC progressors from nonprogressors.
Although very effective, our current capillary-based genotyping approach remains considerably lower throughput and more labor intensive than contemporary massively parallel sequencing platforms. In this study, we examined 17 polyguanine tracts, yet there are more than 3000 comparable sequences throughout the genome that could be simultaneously interrogated on massively parallel sequencing systems to obtain greater sensitivity. The digital nature of next generation sequencing additionally makes it possible to resolve mutant clones that have been substantially intermixed with unrelated cells. This feature might conceivably offer the possibility of collecting samples through less invasive means that ordinarily obscure clone homogeneity, such as colonic brushings or perhaps even DNA from stool. One concern is that the biochemical property which makes polyguanine homopolymers so mutable in vivo-and therefore such informative markers of cell lineage-also occurs during enzymatic manipulation in vitro and has traditionally confounded most next generation sequencers. We and our colleagues have recently developed biochemical error correction techniques that we anticipate will overcome this limitation, 29, 30 and we are working to transition our current assay to this sequencing modality.
In summary, we have validated that clonal expansions in nondysplastic mucosa are a strong biomarker of concurrent cancer in early-onset UC and distinguish UC progressors from nonprogressors with high sensitivity and specificity. Cancer in early-onset UC arises in fields of expanded clones with short telomeres, which are absent in late-onset UC for unclear reasons that merit further elucidation. A lesser degree of clonal expansion also occurs in some nonprogressors, and the extent of this expansion may predict the subset of those patients at greatest risk for future progression. Future longitudinal studies using an assay adapted to higher-throughput massively parallel sequencing platforms will be helpful to confirm this compelling possibility.
